Sleep in chronic insomnia
An older placebo-controlled study reported improvements in sleep measures. The small sample limits how confidently the result can be applied.
Read the publication
Physician-led care in the UAE
Peptide care · Pen
DSIP
Small placebo-controlled insomnia studies produced mixed findings. They do not establish a reliable treatment effect.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
Select the format
Get startedImportant safety informationSuitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Where DSIP
has been studied.
The sleep category reflects direct insomnia studies, although the evidence is old, small and inconsistent.
Consistency of the effect
A later double-blind study found weak or mixed effects. Its authors did not consider the findings evidence of a major therapeutic benefit.
Read the publicationSafety & suitability
Is DSIP right for you?
Limited, short-duration human studies cannot establish long-term sleep-treatment safety.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
DSIP:
what has been studied.
Small sleep studies reported mixed findings. They do not establish a reliable sleep benefit from the subcutaneous preparations shown here.
The small study reported improvements in sleep-related measures.
14 people with chronic insomnia · See original study
What remains uncertain
Read the studyThe sample was small and later findings were less convincing.
The study found only weak or mixed sleep effects.
16 people with chronic insomnia · Intravenous
What remains uncertain
Read the studyThe authors did not consider the findings evidence of a major therapeutic benefit.
About this evidence review
The cited work does not establish the effectiveness of the proposed subcutaneous pen or vial. The later trial used intravenous DSIP.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss DSIP. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
Could my sleep symptoms need a thyroid assessment or evaluation of another underlying cause?
03
Your follow-up
How will we review the plan?
What should I record about sleep, daytime function and any changes before our review?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is DSIP considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
Which DSIP format is right for me?
The cited work does not establish the effectiveness of the proposed subcutaneous pen or vial. The later trial used intravenous DSIP.
What should I know about the safety of DSIP?
Limited, short-duration human studies cannot establish long-term sleep-treatment safety.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other compounds discussed in these health topics, with the evidence for each.
DarDoc peptidesHealthy aging · Sleep & focus
Epitalon
Cell studies examine telomerase activity. An older clinical report explored a retinal condition, but human longevity benefits remain unestablished.
DarDoc peptidesSleep & focus
Dihexa
An independent mouse study reported cognitive findings. Human benefits remain unestablished, and a prominent earlier mechanistic paper was retracted.
DarDoc peptidesSleep & focus
Semax
Human work has explored recovery after ischemic stroke and brain-connectivity measures, rather than everyday concentration.
Bring your questions
Make your next step
a conversation.
Want to understand where DSIP fits? Discuss the evidence, your health history and the options with DarDoc.
